Mitsubishi Mirage Bows Out With Shockingly Low Prices
Mitsubishi Mirage Is Leaving America With Dirt-Cheap Pricing
The Mitsubishi Mirage has held the title of America's cheapest new car for years, but its reign is almost over. Mitsubishi confirmed last year that production of the Mirage, both the hatchback and the G4 sedan, would end by late 2024, with no 2025 model coming to US showrooms. That alone is a major shift for the budget car segment.
Dealers still sell the humble nameplate, with a base MSRP of $16,695 for the hatch and $17,795 for the sedan, undercutting everyone. But there's a bigger twist: dealers are slashing prices even further. Right now, the cheapest new car in America is not just affordable – it's shockingly cheap.
View the 2 images of this gallery on the original article
Dealers Are Letting the Mirage Go for Less Than Used Car Money
A quick scan through listings on Cars.com reveals just how steep the discounts have become. Some new Mirage hatchbacks are being listed for under $12,000 – brand-new, with full factory warranty and delivery mileage.
Even the Mirage G4 sedan, which traditionally had a slightly higher MSRP, is showing deep discounts across the board. Listings with $3,000 to $5,000 off MSRP are common, and some sedans are going for below $13,000, making them cheaper than many used Honda Civics or Toyota Corollas from five years ago.
While these fire-sale prices vary depending on location and dealer strategy, it's clear that Mitsubishi's final batches of Mirages are being moved quickly and aggressively. For someone looking for basic, reliable transportation on a tight budget, this is the best time to get one.
View the 2 images of this gallery on the original article
The End of Sub-$20K Cars Is Near
Once the Mirage disappears from showrooms, which is expected as soon as inventories dry up. There will be just one car left under the $20,000 mark: the Nissan Versa. But even that title is slipping.
Due to new US tariffs affecting vehicles built in Mexico (where the Versa is assembled), Nissan is ending the manual transmission version and raising base prices. Current 2025 models with CVT already flirt with the $20K line, and that's before further pricing updates or inflation.
With the Mirage gone and the Versa climbing in price, the era of the sub-$20,000 new car in America is effectively ending. What replaces it are entry-level models in the low $20K range – better equipped, but notably more expensive. For the absolute lowest cost of entry into new car ownership, the Mirage's final stretch may be your last real chance.
Mitsubishi Mirage Bows Out With Shockingly Low Prices first appeared on Autoblog on Jul 20, 2025
This story was originally reported by Autoblog on Jul 20, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Nvidia Restarts China AI Chip Sales--but Supply Crisis Looms
July 21 - Nvidia (NASDAQ:NVDA) faces a rocky China comeback as it revives H20 AI chip sales, but warns of constrained supply and shifting geopolitics. The company informed Chinese customers that H20 stock is limited and it won't resume production immediately. The H20 is the most powerful AI chip Nvidia is legally permitted to export to China. Warning! GuruFocus has detected 4 Warning Signs with NVDA. U.S. authorities recently lifted export restrictions amid rare-earths talks, but Nvidia cautioned that restocking H20 supply could take up to nine months if it restarts production, citing TSMC shifting its capacity. The chip's return sparked a scramble among Chinese AI firms, including Alibaba, Tencent, Baidu, and ByteDance, eager for access, though H20 is technically inferior to Nvidia's high-end H100 and H200 variants. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Why Bruker (BRKR) Shares Are Getting Obliterated Today
What Happened? Shares of scientific instrument company Bruker (NASDAQ:BRKR). fell 13.8% in the afternoon session after the company released disappointing preliminary second-quarter financial results, which pointed to a significant drop in earnings and a decline in organic revenue. The scientific instrument maker announced that it expects second-quarter revenue to be between $795 million and $798 million, roughly flat compared to the same period last year. However, on an organic basis, which excludes impacts from currency and acquisitions, revenue is projected to have declined by approximately 7%. The company also anticipates non-GAAP earnings per share (EPS) in the range of $0.32 to $0.34, a steep fall of about $0.19 from the prior year. Bruker attributed the weak performance to soft demand from academic institutions and a slowdown in the U.S. biopharma market, which impacted quarterly bookings. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Bruker? Access our full analysis report here, it's free. What Is The Market Telling Us Bruker's shares are quite volatile and have had 16 moves greater than 5% over the last year. But moves this big are rare even for Bruker and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 4.7% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Bruker is down 40.2% since the beginning of the year, and at $35.16 per share, it is trading 50.2% below its 52-week high of $70.67 from September 2024. Investors who bought $1,000 worth of Bruker's shares 5 years ago would now be looking at an investment worth $835.15. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
3 minutes ago
- Yahoo
Why Avantor (AVTR) Shares Are Trading Lower Today
What Happened? Shares of life sciences company Avantor (NYSE:AVTR) fell 8% in the afternoon session after the company announced that it has appointed Emmanuel Ligner as its new President and Chief Executive Officer, effective August 18, 2025. Ligner will succeed Michael Stubblefield, whose departure was previously announced. The news of a leadership change, particularly one that brings in a CEO with no prior public company experience, appears to have created uncertainty among investors. Wolfe Research noted that while Ligner's extensive experience in bioprocessing is a strategic fit for Avantor, his lack of public company CEO experience might lead to investor scrutiny. The firm also highlighted that the absence of updated financial guidance alongside the announcement would likely "raise questions" for investors, who often react negatively to a lack of forward-looking statements during executive transitions.,. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Avantor? Access our full analysis report here, it's free. What Is The Market Telling Us Avantor's shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock dropped 21.2% on the news that the company reported a weak first-quarter 2025 performance, as its organic revenue and total sales both missed Wall Street's expectations. Sales dropped 6% from a year ago, reflecting softness across both major business segments. Lab Solutions declined 8% while Bioscience Production slipped slightly. Encouragingly, management raised its cost savings target to $400 million by 2027 and signaled urgency to fix performance issues in the Lab Solutions segment. Still, this was a softer quarter. Avantor is down 42.3% since the beginning of the year, and at $12.23 per share, it is trading 55.9% below its 52-week high of $27.70 from September 2024. Investors who bought $1,000 worth of Avantor's shares 5 years ago would now be looking at an investment worth $655.14. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
